0000000000362576

AUTHOR

Silvana Leo

showing 8 related works from this author

Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives

2017

urpose Everolimus has been shown to be effective for advanced pancreatic neuroendocrine tumours (pNETs), but its positioning in the therapeutic algorithm for pNETs is matter of debate. Methods With the aim to shed light on this point, we performed an up-to-date critical review taking into account the results of both retrospective and prospective published studies, and the recommendations of international guidelines. In addition, we performed an extensive search on the Clinical Trial Registries databases worldwide, to gather information on the ongoing clinical trials related to this specific topic. Results We identified eight retrospective published studies, two prospective published studies…

0301 basic medicinemTOR inhibitorsCancer Researchmedicine.medical_specialtyPathologymTOR inhibitorEverolimus; mTOR inhibitors; Neuroendocrine tumours; Therapy; Antineoplastic Agents; Everolimus; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Oncology; Cancer ResearchTherapeutic algorithmEverolimus; mTOR inhibitors; neuroendocrine tumours; therapy; antineoplastic agents; everolimus; humans; neuroendocrine tumours; pancreatic neoplasms; oncology; cancer researchEndocrine SyndromeNeuroendocrine tumorsAntineoplastic Agent03 medical and health sciences0302 clinical medicineFirst line therapyNeuroendocrine tumourantineoplastic agentsmedicinehumansIntensive care medicinetherapyEverolimusbusiness.industryPancreatic Neoplasmpancreatic neoplasmsGeneral Medicineeverolimusmedicine.diseaseDiscovery and development of mTOR inhibitorsClinical trialEverolimuNeuroendocrine Tumors030104 developmental biologyOncology030220 oncology & carcinogenesisneuroendocrine tumoursNeuroendocrine TumorbusinessEverolimus; mTOR inhibitors; Neuroendocrine tumours; Therapy; Antineoplastic Agents; Everolimus; Humans; Neuroendocrine Tumors; Pancreatic NeoplasmsHumanmedicine.drugJournal of Cancer Research and Clinical Oncology
researchProduct

Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Onc…

2009

Purpose: This phase II trial assessed the tolerability and efficacy of a triplet of oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer. Methods: Patients with unresectable or metastatic gastric cancer, unexposed to palliative chemotherapy, received oxaliplatin 85 mg/m 2 iv and irinotecan 150 mg/m2 iv on day 1, 6S-folinic acid 250 mg/m2 iv and fluorouracil 750 mg/m2 iv on day 2, every 2 weeks. Response rate (RR) was assessed after a minimum of four cycles, and treatment continued up to 12 cycles. Results: Sixty-three patients were treated, with a median of eight (range 1-12) cycles/patient. Two complete and 19 partial responses were registered (RR 33% [95% CI, …

OncologyMaleCancer ResearchOrganoplatinum CompoundsAntimetabolitesSettore MED/06 - Oncologia Medicamedicine.medical_treatmentAntidotesLeucovorinKaplan-Meier EstimateToxicologyPhytogenicAntineoplastic Combined Chemotherapy Protocols80 and overMedicinePharmacology (medical)Stomach cancerTomographyAged 80 and overMiddle AgedAntineoplasticMagnetic Resonance ImagingX-Ray ComputedOxaliplatinOncologyFluorouracilFemaleFluorouracilmedicine.drugAdultmedicine.medical_specialtyAntimetabolites AntineoplasticAntineoplastic AgentsNeutropeniaAdenocarcinomaIrinotecanFolinic acidStomach NeoplasmsTomography X-Ray Computed; Male; Aged 80 and over; Antimetabolites Antineoplastic; Middle Aged; Kaplan-Meier Estimate; Camptothecin; Survival Analysis; Female; Fluorouracil; Adenocarcinoma; Leucovorin; Humans; Organoplatinum Compounds; Antineoplastic Agents; Stomach Neoplasms; Magnetic Resonance Imaging; Antidotes; Blood Cell Count; Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Agents Phytogenic; Aged; AdultInternal medicineHumansAgedPharmacologyChemotherapybusiness.industryGastric cancerFluorouracilIrinotecan OxaliplatinTriplet regimenmedicine.diseaseAntineoplastic Agents PhytogenicSurvival Analysisdigestive system diseasesOxaliplatinBlood Cell CountIrinotecanCamptothecinbusinessTomography X-Ray ComputedFebrile neutropeniaCancer chemotherapy and pharmacology
researchProduct

Cisplatin-based first-line treatment of elderly patients with advanced non-small-cell lung cancer: Joint analysis of MILES-3 and MILES-4 phase III tr…

2018

Purpose To test the efficacy of adding cisplatin to first-line treatment for elderly patients with advanced non–small-cell lung cancer (NSCLC) within a combined analysis of two parallel phase III trials, MILES-3 and MILES-4. Patients and Methods Patients with advanced NSCLC who were older than age 70 years with Eastern Cooperative Oncology Group performance status 0 to 1 were randomly assigned to gemcitabine or pemetrexed, without or with cisplatin. In each trial, 382 events were required to detect a hazard ratio (HR) of death of 0.75, with 80% power and two-tailed α of .05. Trials were closed prematurely because of slow accrual, but the joint database allowed us to analyze the efficacy of …

0301 basic medicineOncologyMaleCancer Researchmedicine.medical_specialtyPhases of clinical researchKaplan-Meier EstimatePemetrexedDeoxycytidine03 medical and health sciences0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell Lungmedicineadvanced non small cell lung cancer (NSCLC) elderly patients cisplatin MILES 3 MILES 4Progression-free survivalLung cancerSurvival rateAgedAged 80 and overAntineoplastic Combined Chemotherapy ProtocolPerformance statusbusiness.industrymedicine.diseaseGemcitabineLung Neoplasm030104 developmental biologyPemetrexedTreatment OutcomeOncologyResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisQuality of LifeFemaleCisplatinbusinessmedicine.drugHuman
researchProduct

Safety and efficacy of irinotecan plus high-dose leucovorin and intravenous bolus 5-fluorouracil for metastatic colorectal cancer: pooled analysis of…

2005

Abstract Background A biweekly regimen of irinotecan 200 mg/m2 on day 1 and levo-leucovorin (LV) 250 mg/m2 plus 5-fluorouracil (5-FU) 850 mg/m2 via intravenous bolus on day 2 was assessed in 2 consecutive randomized trials in metastatic colorectal cancer (CRC). Patients and Methods Individual data of 254 patients were merged, and baseline features potentially affecting overall response rate (ORR), progression-free survival (PFS),overall survival (OS), and occurrence of severe toxicity were analyzed by univariate and multivariate analyses. Results In the pooled series, ORR was 33% (95% confidence interval [CI], 27%-39%). Liver-only disease (47% vs. 25%; P = 0.0012) and absence of previous we…

OncologyAdultMalemedicine.medical_specialtySettore MED/06 - Oncologia MedicaLeucovorinNeutropeniaIrinotecanDrug Administration ScheduleInjectionsWeight lossInternal medicineAntineoplastic Combined Chemotherapy ProtocolsWeight Loss80 and overMedicineHumansNeoplasm MetastasisAgedAged 80 and overPerformance statusbusiness.industryHazard ratioGastroenterologyAge FactorsMiddle Agedmedicine.diseaseOxaliplatinIrinotecanRegimenTreatment OutcomeOncologyFluorouracilInjections IntravenousCamptothecinFemaleFluorouracilAge Factors; Drug Administration Schedule; Injections Intravenous; Humans; Aged; Leucovorin; Camptothecin; Aged 80 and over; Fluorouracil; Weight Loss; Adult; Treatment Outcome; Neoplasm Metastasis; Antineoplastic Combined Chemotherapy Protocols; Middle Aged; Male; Colorectal Neoplasms; Femalemedicine.symptomIntravenousbusinessColorectal Neoplasmsmedicine.drugClinical colorectal cancer
researchProduct

Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey

2013

BackgroundBone metastasis represents an increasing clinical problem in advanced gastric cancer (GC) as disease-related survival improves. In literature, few data on the natural history of bone disease in GC are available.Patients and methodsData on clinicopathology, skeletal outcomes, skeletal-related events (SREs), and bone-directed therapies for 208 deceased GC patients with evidence of bone metastasis were statistically analyzed.ResultsMedian time to bone metastasis was 8 months (CI 95%, 6.125-9.875 months) considering all included patients. Median number of SREs/patient was one. Less than half of the patients (31%) experienced at least one and only 4 and 2% experienced at least two and …

OncologyAdultMalemedicine.medical_specialtyPathologyBone diseaseSettore MED/06 - Oncologia Medicamedicine.medical_treatmentScienceBone NeoplasmsMetastasisgastric cancer; bone metastasisStomach NeoplasmsInternal medicinemedicineHumansskeletal disease advanced hepatocellular carcinomaskeletal-related events bisphosphonateAdult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Patient Outcome Assessment; Population Surveillance; Prognosis; Retrospective Studies; Stomach NeoplasmsNeoplasm Metastasisbone metastasisAgedRetrospective StudiesMultidisciplinaryBone Density Conservation AgentsDiphosphonatesbusiness.industrygastric cancerQRBone metastasisCancerBone fractureMiddle Agedmedicine.diseasePrognosisRadiation therapyPatient Outcome AssessmentBone Density Conservation AgentsZoledronic acidPopulation SurveillanceMedicineFemalebusinessmedicine.drugResearch Article
researchProduct

Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group

2019

Purpose: Many different treatments are suggested by guidelines to treat grade 1−2 (G1−G2) neuroendocrine tumors (NET). However, a precise therapeutic algorithm has not yet been established. This study aims at identifying and comparing the main therapeutic sequences in G1−G2 NET. Methods: A retrospective observational Italian multicenter study was designed to collect data on therapeutic sequences in NET. Median progression-free survival (PFS) was compared between therapeutic sequences, as well as the number and grade of side effects and the rate of dose reduction/treatment discontinuation. Results: Among 1182 patients with neuroendocrine neoplasia included in the ELIOS database, 131 G1–G2 ga…

MaleOncologymedicine.medical_specialtyHigh-dose somatostatin analogs; neuroendocrine tumors; PRRT; sequence of treatments; somatostatin analogues; targeted therapyLung NeoplasmsDatabases FactualSettore MED/06 - Oncologia MedicaEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAntineoplastic AgentsHigh-dose somatostatin analogNeuroendocrine tumorsOctreotideSomatostatin analogueTargeted therapySettore MED/13 - EndocrinologiaTargeted therapyEndocrinologyNeuroendocrine tumorStomach NeoplasmsInternal medicineDiabetes mellitusIntestinal NeoplasmsSequence of treatmentmedicineHumansEverolimusRetrospective StudiesChemotherapyEverolimusbusiness.industryDisease ManagementMiddle Agedmedicine.diseaseDiscontinuationPancreatic NeoplasmsNeuroendocrine TumorsRadionuclide therapyFemaleObservational studyPRRTSomatostatinbusinessmedicine.drug
researchProduct

Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell l…

2019

Abstract Objectives To evaluate the effect on quality of life (QOL) of the addition of cisplatin to single-agent chemotherapy in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC) enrolled in two parallel phase 3 trials, MILES-3 and MILES-4. Patients and methods Advanced NSCLC pts, >70 years old, performance status (PS) 0–1, were eligible. Patients were randomly assigned to chemotherapy without or with cisplatin. EORTC QLQ C30 and LC13 questionnaires were planned at baseline, end of cycle 1 and end of cycle 2 in both trials and were used for joint QOL analysis. Trial-specific data including questionnaires at non-shared time-points were used for additional ana…

0301 basic medicinePulmonary and Respiratory MedicineQuality of lifeMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsNauseamedicine.medical_treatmentRandomizedNSCLCPhase 303 medical and health sciences0302 clinical medicineQuality of lifeInternal medicineSurveys and QuestionnairesCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansSurveys and QuestionnaireLung cancerAgedNeoplasm StagingCisplatinAged 80 and overChemotherapyAntineoplastic Combined Chemotherapy ProtocolPerformance statusbusiness.industryAlopeciamedicine.diseaseDysphagiaLung Neoplasm030104 developmental biologyTreatment OutcomeOncology030220 oncology & carcinogenesisVomitingStomatitis AphthousFemalemedicine.symptomCisplatinbusinessElderly patientStomatitis Aphthoumedicine.drugHuman
researchProduct

First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: A quality of life directed phase II randomiz…

2009

Abstract Background Quality of life (QoL) has gained greater importance in the management of metastatic non-small-cell lung cancer due to the palliative nature of treatment. Docetaxel (DCT) and cisplatin (CDDP) doublet has been reported to be associated to a better QoL than the weekly vinorelbine (VNR) and CDDP regimen. Recently a newer more tolerated schedule of the VNR/CDDP regimen has been published and is widely employed in medical practice. The impact of these regimens on patients' QoL as well as symptoms control and type and grading chemo-related side-effects has been compared prospectically. Methods Patients received CDDP 75mg/m 2 plus DCT 75mg/m 2 on day 1 every weeks (arm A) or CDD…

AdultMalePulmonary and Respiratory MedicineOncologyCancer Researchmedicine.medical_specialtyLung NeoplasmsNeutropeniamedicine.medical_treatmentDocetaxelNeutropeniaVinblastineVinorelbineClinical ProtocolsQuality of lifeCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansLung cancerneoplasmsAgedChemotherapybusiness.industryAnemiaVinorelbineMiddle Agedmedicine.diseaseSurvival AnalysisSurgeryRegimenOncologyDocetaxelDisease ProgressionQuality of LifeFemaleTaxoidsCisplatinbusinessFebrile neutropeniamedicine.drugLung Cancer
researchProduct